Clinical Trial Update: Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone Treatment [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluated whether intratympanic dexamethasone can prevent cisplatin-induced ototoxicity (hearing loss) after cisplatin therapy; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cisplatin-induced Ototoxicity
• Hearing Loss

Drugs mentioned

• Dexamethasone (intratympanic) (dexamethasone)

Snippet

Sponsor: Meir Medical Center | Conditions: Cisplatin Ototoxicity | Phase 4 | Status: COMPLETED